Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $50.89 USD
Change Today -0.65 / -1.26%
Volume 850.0K
ISIS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 1:57 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

2855 Gazelle Court

Carlsbad, CA 92010

United States

Phone: 760-931-9200

Fax:

Isis Pharmaceuticals, Inc. engages in the discovery and development of a class of RNA (ribonucleic acid)-targeted drugs called antisense drugs using novel drug discovery platform. Drug Discovery and Development Development Projects KYNAMRO (mipomersen sodium) Injection The company’s novel lipid-lowering product, KYNAMRO (mipomersen sodium) injection, is on the market in the United States for patients with homozygous familial hypercholesterolemia (HoFH). In 2013, the U.S. Food and Drug Administration (FDA) approved the marketing application for KYNAMRO for patients with HoFH. Genzyme Corporation (Genzyme), a Sanofi Company, has also obtained marketing approval in other countries, including Mexico, Argentina, South Korea, and Peru; and is pursuing marketing approval in multiple additional markets. Genzyme has obtained marketing approval for KYNAMRO in the United States, South Korea, Argentina, Mexico, and Peru for use in patients with HoFH and is continuing to pursue approval in multiple additional markets. KYNAMRO is a novel, first-in-class, apo-B synthesis inhibitor for the reduction of low-density lipoprotein cholesterol. Severe and Rare Disease Franchise The company is discovering and developing antisense drugs to treat severe and rare and neurological diseases for which there is a need for new treatment options. The company’s strategic partnerships with Biogen Idec and Roche have supported advancing five drugs for the treatment of neuromuscular or neurological diseases in the company’s pipeline. Alicaforsen Alicaforsen is an antisense drug designed to target the intercellular adhesion molecule 1 (ICAM-1). ICAM-1 is over-expressed in various inflammatory disorders, including ulcerative colitis (UC) and pouchitis. The company licensed alicaforsen to Atlantic Pharmaceuticals Limited for pouchitis, UC, and other inflammatory diseases. The FDA and European Medicines Agency have since granted alicaforsen Orphan Drug Designation for the treatment of pouchitis in the United States and Europe, respectively. Atlantic Pharmaceuticals Limited is pursuing opportunities to fund further development of alicaforsen. ISIS-TTRRx ISIS-TTRRx is an antisense drug that the company designed to treat transthyretin amyloidosis (TTR) amyloidosis, a severe and rare genetic disease in which the patient inherits a mutant gene that produces a misfolded form of TTR, which progressively accumulates in tissues. The company is evaluating ISIS-TTRRx to treat two types of TTR amyloidosis, familial amyloid cardiomyopathy (FAC) and familial amyloid polyneuropathy (FAP). The company completed a Phase 1 study evaluating the safety and activity of ISIS-TTRRx in healthy volunteers. In 2013, the company initiated a randomized, double-blind, placebo-controlled 15-month Phase 3 study of ISIS-TTRRx in patients with FAP. The company plans to report data in 2017. The company’s partner, GSK, also plans to evaluate ISIS-TTRRx in patients with FAC and is in the planning stages of a Phase 3 study for this indication. ISIS-SMNRx ISIS-SMNRx is an antisense drug that the company designed to treat spinal muscular atrophy (SMA), a severe motor-neuron disease that is the leading genetic cause of infant mortality. The company designed ISIS-SMNRx to potentially treat all types of childhood SMA by altering the splicing of a closely related gene, SMN2, which leads to the increased production of fully functional SMN protein. The company developed a biomarker assay to measure levels of SMN protein in the cerebral spinal fluid of children and infants with SMA. The company is evaluating ISIS-SMNRx in a Phase 2 open-label, multiple-dose, dose-escalation study in children with SMA. It is also evaluating ISIS-SMNRx in a Phase 2 open-label, multiple-dose, dose-escalation study in 20 infants who have been diagnosed with SMA. The company is evaluating ISIS-SMNRx in two Phase 3 studies in infants and children with SMA. The company designed these studies to support marketing registration for ISIS-SMNRx in the United States and Europe. The Phase 3 study, ENDEAR, is a randomized, double-blind, sham-procedure controlled 13-month study in approximately

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISIS:US $50.89 USD -0.65

ISIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ACADIA Pharmaceuticals Inc $37.55 USD -0.62
Acorda Therapeutics Inc $32.21 USD -0.52
Alnylam Pharmaceuticals Inc $105.59 USD -3.48
Depomed Inc $27.49 USD -0.89
Impax Laboratories Inc $41.30 USD -1.10
View Industry Companies
 

Industry Analysis

ISIS

Industry Average

Valuation ISIS Industry Range
Price/Earnings 100.0x
Price/Sales 19.8x
Price/Book 20.6x
Price/Cash Flow 265.3x
TEV/Sales 15.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISIS PHARMACEUTICALS INC, please visit www.isispharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.